[Summary] Artificial heart R&D enterprise
Suzhou Heartcon Medical Technology Co., Ltd. (hereinafter referred to as "Heartcon") was established in 2008. It focuses on the research, development, production and sales of technically breakthrough ventricular assist devices (also known as "VAD" or "artificial heart"). By continuously providing excellent services to professional medical teams and patients, it is committed to becoming a technology company that leads the progress of the global artificial heart industry and promotes healthy and happy lives for a wider range of heart failure patients and their families worldwide.
After more than ten years of development, relying on independent innovation and technological accumulation in the field of fully magnetic levitation artificial hearts, Heartcon has completed the development of a new-generation implantable left ventricular assist device based on fully magnetic levitation technology — CH-VAD®. The product was approved for marketing by China's National Medical Products Administration (NMPA) in November 2021. The company's implantable ventricular assist device products, due to their globally advanced technology and patent protection, filled the gap in the research, development, production and application of artificial hearts in China, and were evaluated by the NMPA as a "domestic first".
Through an original optimized design integrating magnetic levitation and fluid dynamics, the product achieves the blood compatibility potential indicated by fully magnetic levitation and has demonstrated excellent blood compatibility in clinical applications. Compared with international products of the same technology category, CH-VAD® has a smaller blood pump size, improved implant invasiveness, and a thinner percutaneous cable, which helps improve infection prevention performance. CH-VAD® has reached international levels in various key performance aspects for evaluating ventricular assist devices. At the same time, the product has a complete independent intellectual property rights built from underlying core technologies. It has completed core patent layouts in countries and regions such as China, the United States, Europe and Japan, laying the foundation for the company's global commercialization layout.
In addition, the company has built a global R&D platform with multidisciplinary optimization design capabilities and product design concepts integrating usability engineering and design for manufacturability (DFM). It has created a high-reliability medical device precision manufacturing system with deep technical accumulation and established a quality management system covering the entire life cycle of high-risk medical devices. At present, the company is establishing an international-level clinical application service system for VAD commercialization, and is taking the lead in carrying out the commercialization process of CH-VAD® in China. It is committed to continuously achieving the company's international commercial layout by coordinating global advantageous resources in the artificial heart field and promoting innovation and development in this field. With the development of the company's international layout, it is expected to change the competitive landscape of the global artificial heart market.
What does Suzhou Heartcon Medical Technology Co., Ltd. require? Who is Heartcon hiring? Heartcon recruitment: 销售类占比最多占43%,其次是经营管理类占39.3%. What education can get in at Heartcon? 本科占比最多占84.4%,其次是大专占12.6%. High education required at Heartcon? 硕士占0.7%. Work experience required at Heartcon? 不限占比最多占45.2%,其次是3-5年占25.2%. Where are the job locations at Heartcon? 苏州占比最多占29.6%,其次是上海占11.1%. Based on job postings from the past year, for reference only.
Congratulations, submitted successfully!
Your edit is under review. You will be notified by email within 1 business day.
Submission failed.
Help others learn about this company, add my impression of this company»
Log in with the following accounts to save your follows